Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
83.05 EUR | +1.28% | -0.36% | -13.81% |
Apr. 25 | Sector Update: Health Care Stocks Drop in Afternoon Trading | MT |
Apr. 25 | GSK Sues Pfizer, BioNTech Over mRNA Patents in Covid-19 Vaccines | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-13.81% | 21.2B | - | ||
-3.46% | 102B | B+ | ||
+1.41% | 96.29B | B+ | ||
+2.13% | 22.18B | B | ||
-9.21% | 18.31B | A- | ||
-39.98% | 17.38B | A- | ||
-14.65% | 16.36B | B | ||
+4.39% | 13.97B | C+ | ||
+31.35% | 12.17B | C+ | ||
+327.62% | 8.32B | - | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BNTX Stock
- 22UA Stock
- Ratings BioNTech SE